| # | Title | Journal | Year | Citations |
|---|
| 1 | Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 | Cell Death and Differentiation | 2018 | 4,036 |
| 2 | Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial | Lancet Oncology, The | 2017 | 1,388 |
| 3 | Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance | Oncogene | 2003 | 690 |
| 4 | American College of Sports Medicine Roundtable Report on Physical Activity, Sedentary Behavior, and Cancer Prevention and Control | Medicine and Science in Sports and Exercise | 2019 | 455 |
| 5 | Molecular Subtypes ofKIT/PDGFRAWild-Type Gastrointestinal Stromal Tumors | JAMA Oncology | 2016 | 291 |
| 6 | Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies | Molecular Cancer Therapeutics | 2018 | 280 |
| 7 | Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma | Blood | 2012 | 278 |
| 8 | Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial | Lancet Oncology, The | 2021 | 225 |
| 9 | Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets | Clinical Cancer Research | 2017 | 215 |
| 10 | Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025 | European Urology | 2017 | 209 |
| 11 | Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC) | Cancer | 2020 | 202 |
| 12 | Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial | Cancer | 2020 | 201 |
| 13 | Relationship of Internet Health Information Use With Patient Behavior and Self-Efficacy: Experiences of Newly Diagnosed Cancer Patients Who Contact the National Cancer Institute's Cancer Information Service | Journal of Health Communication | 2006 | 167 |
| 14 | Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial | Journal of Health Communication | 2020 | 160 |
| 15 | Transformation of Human Breast Epithelial Cells by c-Ha-ras Oncogene | Molecular Carcinogenesis | 1991 | 155 |
| 16 | Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression | JAMA Oncology | 2016 | 154 |
| 17 | Is chronic hepatitis B being undertreated in the United States? | Journal of Viral Hepatitis | 2011 | 153 |
| 18 | Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study | Journal of Viral Hepatitis | 2018 | 151 |
| 19 | Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors | Advances in Therapy | 2019 | 145 |
| 20 | The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types | Cancer | 2020 | 116 |
| 21 | Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden | Cancer | 2018 | 111 |
| 22 | Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors | Oncologist | 2017 | 109 |
| 23 | Weight management and physical activity throughout the cancer care continuum | Ca-A Cancer Journal for Clinicians | 2018 | 109 |
| 24 | ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer | Clinical Cancer Research | 2019 | 104 |
| 25 | Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer | Journal of Clinical Oncology | 2020 | 102 |
| 26 | Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer | Journal of Clinical Oncology | 2017 | 99 |
| 27 | Role of Dopamine Receptors in the Anticancer Activity of ONC201 | Neoplasia | 2018 | 96 |
| 28 | Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer | European Urology | 2019 | 95 |
| 29 | Phase 1 dose‐escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors | Cancer | 2017 | 94 |
| 30 | Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib | Clinical Pharmacokinetics | 2019 | 92 |
| 31 | Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma | Clinical Cancer Research | 2020 | 90 |
| 32 | Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling | European Urology | 2018 | 87 |
| 33 | Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report | Journal of the National Cancer Institute | 2022 | 74 |
| 34 | Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results | JAMA Oncology | 2017 | 73 |
| 35 | Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder‐preservation therapy for muscle‐invasive bladder cancer | Cancer | 2017 | 72 |
| 36 | Perspectives of HER2-targeting in gastric and esophageal cancer | Expert Opinion on Investigational Drugs | 2017 | 71 |
| 37 | Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas | Clinical Colorectal Cancer | 2016 | 67 |
| 38 | Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors | Clinical Colorectal Cancer | 2020 | 62 |
| 39 | Effect of Home-Based Exercise and Weight Loss Programs on Breast Cancer–Related Lymphedema Outcomes Among Overweight Breast Cancer Survivors | JAMA Oncology | 2019 | 61 |
| 40 | A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer | Future Oncology | 2018 | 60 |
| 41 | Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers | Blood | 2021 | 59 |
| 42 | Mutations in renal cell carcinoma | Urologic Oncology: Seminars and Original Investigations | 2020 | 58 |
| 43 | Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapies | American Journal of Hematology | 2017 | 56 |
| 44 | Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study | Journal of Clinical Oncology | 2021 | 56 |
| 45 | Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma | European Journal of Endocrinology | 2022 | 55 |
| 46 | Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212 | Cell Cycle | 2017 | 53 |
| 47 | Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: A non-randomized comparison using an explanatory analysis: A Gynecologic Oncology Group study | Gynecologic Oncology | 2005 | 52 |
| 48 | The Appalachia Cancer Network: Cancer Control Research Among a Rural, Medically Underserved Population | Journal of Rural Health | 2004 | 50 |
| 49 | Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions | Current Urology Reports | 2018 | 47 |
| 50 | Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial | Lancet Haematology,the | 2018 | 44 |
